-+ 0.00%
-+ 0.00%
-+ 0.00%

Nurix reports early clinical NX-1607 target engagement data at AACR 2026

PUBT·04/22/2026 11:07:41
Listen to the news
Nurix reports early clinical NX-1607 target engagement data at AACR 2026
  • Nurix Therapeutics released new preclinical oncology data at AACR 2026, with results already presented in posters and an oral session.
  • NRX-0305 showed strong anti-tumor activity in brain cancer models, including in settings resistant to existing BRAF drugs.
  • NX-1607 demonstrated immune-activating effects in preclinical studies, with early clinical findings indicating target engagement in patients.
  • NRX-4972 delivered better tumor control than AURKA inhibitors in an aggressive small cell lung cancer model, supporting continued development of Nurix’s degrader approach.
  • Gwenn Hansen is scheduled to present an AACR Advances session talk later today on lessons from early clinical experience with degrader therapeutics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220700PRIMZONEFULLFEED9694745) on April 22, 2026, and is solely responsible for the information contained therein.